BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017;2:325-36. [PMID: 28397696 DOI: 10.1016/S2468-1253(17)30045-6] [Cited by in Crossref: 145] [Cited by in F6Publishing: 60] [Article Influence: 29.0] [Reference Citation Analysis]
Number Citing Articles
1 Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? J Int AIDS Soc. 2017;20:22146. [PMID: 28782335 DOI: 10.7448/ias.20.1.22146] [Cited by in Crossref: 74] [Cited by in F6Publishing: 32] [Article Influence: 14.8] [Reference Citation Analysis]
2 Seo HY, Seo MS, Yoon SY, Choi JW, Ko SY. Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis. Korean J Intern Med 2020;35:559-65. [PMID: 31064176 DOI: 10.3904/kjim.2018.338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lim AG, Qureshi H, Mahmood H, Hamid S, Davies CF, Trickey A, Glass N, Saeed Q, Fraser H, Walker JG, Mukandavire C, Hickman M, Martin NK, May MT, Averhoff F, Vickerman P. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination. Int J Epidemiol 2018;47:550-60. [PMID: 29309592 DOI: 10.1093/ije/dyx270] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
4 Tavoschi L, Mason L, Petriti U, Bunge E, Veldhuijzen I, Duffell E. Hepatitis B and C among healthcare workers and patient groups at increased risk of iatrogenic transmission in the European Union/European Economic Area. J Hosp Infect 2019;102:359-68. [PMID: 30885816 DOI: 10.1016/j.jhin.2019.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Busschots D, Toghanian S, Bielen R, Salomonsson S, Koc ÖM, Hendrickx G, Jadoul M, Nevens F, Sokal E, Brixko C, Peerlinck K, Apers L, Robaeys G, Lazarus JV. Eliminating viral hepatitis C in Belgium: the micro-elimination approach. BMC Infect Dis 2020;20:181. [PMID: 32106819 DOI: 10.1186/s12879-020-4898-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
6 Cabezas J, Llerena S, Mateo M, Álvarez R, Cobo C, González V, Martró E, Cuadrado A, Crespo J. Hepatitis C Micro-Elimination beyond Prison Walls: Navigator-Assisted Test-and-Treat Strategy for Subjects Serving Non-Custodial Sentences. Diagnostics (Basel) 2021;11:877. [PMID: 34068955 DOI: 10.3390/diagnostics11050877] [Reference Citation Analysis]
7 Abu-Freha N, Mathew Jacob B, Elhoashla A, Afawi Z, Abu-Hammad T, Elsana F, Paz S, Etzion O. Chronic hepatitis C: Diagnosis and treatment made easy. Eur J Gen Pract 2022;28:102-8. [PMID: 35579223 DOI: 10.1080/13814788.2022.2056161] [Reference Citation Analysis]
8 Maticic M, Zorman JV, Gregorcic S, Schatz E, Lazarus JV. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries. Harm Reduct J 2019;16:32. [PMID: 31072401 DOI: 10.1186/s12954-019-0303-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
9 Minosse C, Gruber CEM, Rueca M, Taibi C, Zaccarelli M, Grilli E, Montalbano M, Capobianchi MR, Antinori A, D'Offizi G, McPhee F, Garbuglia AR. Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses 2021;13:1151. [PMID: 34208646 DOI: 10.3390/v13061151] [Reference Citation Analysis]
10 Delile JM, de Ledinghen V, Jauffret-Roustide M, Roux P, Reiller B, Foucher J, Dhumeaux D. Hepatitis C virus prevention and care for drug injectors: the French approach. Hepatol Med Policy 2018;3:7. [PMID: 30288330 DOI: 10.1186/s41124-018-0033-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
11 Allen N, Faherty C, Davies A, Lyons A, Scarry M, Bohan Keane M, Boyle N, O'Connell S, McCarthy E, Keady D, Bergin C, Lee J, Fleming C, Gallagher D, Tuite H. Opt-out bloodborne virus screening: a cross-sectional observational study in an acute medical unit. BMJ Open 2019;9:e022777. [PMID: 31315851 DOI: 10.1136/bmjopen-2018-022777] [Reference Citation Analysis]
12 Mason LM, Duffell E, Veldhuijzen IK, Petriti U, Bunge EM, Tavoschi L. Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review. Euro Surveill 2019;24. [PMID: 31362808 DOI: 10.2807/1560-7917.ES.2019.24.30.1800614] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
13 Chen Q, Ayer T, Bethea E, Kanwal F, Wang X, Roberts M, Zhuo Y, Fagiuoli S, Petersen J, Chhatwal J. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019;9:e026726. [PMID: 31189677 DOI: 10.1136/bmjopen-2018-026726] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
14 Smets I, Giovannoni G. Derisking CD20-therapies for long-term use. Mult Scler Relat Disord 2021;57:103418. [PMID: 34902761 DOI: 10.1016/j.msard.2021.103418] [Reference Citation Analysis]
15 Juanbeltz R, Pérez-García A, Aguinaga A, Martínez-Baz I, Casado I, Burgui C, Goñi-Esarte S, Repáraz J, Zozaya JM, San Miguel R, Ezpeleta C, Castilla J; EIPT-VHC Study Group. Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain. PLoS One 2018;13:e0208554. [PMID: 30513107 DOI: 10.1371/journal.pone.0208554] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
16 Idilman R, Razavi H, Robbins-Scott S, Akarca US, Örmeci N, Kaymakoglu S, Aygen B, Tozun N, Güner R, Bodur H, Lazarus JV. A micro-elimination approach to addressing hepatitis C in Turkey. BMC Health Serv Res 2020;20:249. [PMID: 32209103 DOI: 10.1186/s12913-020-5019-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Sultana C, Rosca A, Ruta S. Correlation Between miR-125b Expression and Liver Fibrosis in Patients with Chronic Hepatitis C. Hepat Mon 2019;In Press. [DOI: 10.5812/hepatmon.84615] [Reference Citation Analysis]
18 Fagan O, Armstrong P, Merwe KVD, Crosnoi D, Steele C, Sopena-Falco J, Parihar V. Viral hepatitis: A brief introduction, review of management, advances and challenges. World J Meta-Anal 2021; 9(2): 139-152 [DOI: 10.13105/wjma.v9.i2.139] [Reference Citation Analysis]
19 Stocks T, Martin LJ, Kühlmann-Berenzon S, Britton T. Dynamic modeling of hepatitis C transmission among people who inject drugs. Epidemics 2019;30:100378. [PMID: 31864130 DOI: 10.1016/j.epidem.2019.100378] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Pericàs JM, Bromberg DJ, Ocampo D, Schatz E, Wawer I, Wysocki P, Safreed-Harmon K, Lazarus JV. Hepatitis C services at harm reduction centres in the European Union: a 28-country survey. Harm Reduct J 2019;16:20. [PMID: 30898122 DOI: 10.1186/s12954-019-0290-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Safreed-Harmon K, Hetherington KL, Aleman S, Alho H, Dalgard O, Frisch T, Gottfredsson M, Weis N, Lazarus JV; Hep-Nordic Study Group. Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. PLoS One 2018;13:e0190146. [PMID: 29381697 DOI: 10.1371/journal.pone.0190146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Giacomelli A, Pagani G, Conti F, Bassoli C, Galli M. Detecting HCV infection by means of mass population SARS-CoV-2 screening: a pilot experience in Northern Italy. J Hepatol. 2021;. [PMID: 33453329 DOI: 10.1016/j.jhep.2020.12.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Fourati S, Feld JJ, Chevaliez S, Luhmann N. Approaches for simplified HCV diagnostic algorithms. J Int AIDS Soc 2018;21 Suppl 2:e25058. [PMID: 29633561 DOI: 10.1002/jia2.25058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
24 Brady Z, Stoykova Z. Hepatitis C virus genotype analysis in patients with chronic hepatitis in North Eastern Bulgaria. J Drug Assess. 2019;8:146-149. [PMID: 31552145 DOI: 10.1080/21556660.2019.1654484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Greenaway C, Makarenko I, Chakra CNA, Alabdulkarim B, Christensen R, Palayew A, Tran A, Staub L, Pareek M, Meerpohl JJ, Noori T, Veldhuijzen I, Pottie K, Castelli F, Morton RL. The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review. Int J Environ Res Public Health 2018;15:E2013. [PMID: 30223539 DOI: 10.3390/ijerph15092013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
26 Piazzolla AV, Paroni G, Bazzocchi F, Cassese M, Cisternino A, Ciuffreda L, Gorgoglione F, Gorgoglione L, Palazzo V, Sciannamè N, Taurchini M, Vaira P, Cocomazzi G, Squillante MM, Aucella F, Cascavilla N, De Cosmo S, Fania M, Greco A, Laborante A, Leone M, Maiello E, Salvatori M, Di Mauro L, Mangia A. High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55-85. Pathogens 2021;10:695. [PMID: 34205096 DOI: 10.3390/pathogens10060695] [Reference Citation Analysis]
27 Schmidbauer C, Schwarz M, Schütz A, Schubert R, Schwanke C, Gutic E, Pirker R, Lang T, Reiberger T, Haltmayer H, Gschwantler M. Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy. PLoS One 2021;16:e0252274. [PMID: 34086708 DOI: 10.1371/journal.pone.0252274] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Federico A, Dallio M, Caprio GG, de Sio I, Cotticelli G, Esposito P, Loguercio C. A Real-Life Study of New Antiviral Therapies in a High Prevalence Geographical Area for Hepatitis C Virus Infection. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.74224] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Han R, Liang S, François C, Aballea S, Clay E, Toumi M. Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach. J Mark Access Health Policy 2021;9:1887664. [PMID: 33828822 DOI: 10.1080/20016689.2021.1887664] [Reference Citation Analysis]
30 Schmidbauer C, Schubert R, Schütz A, Schwanke C, Luhn J, Gutic E, Pirker R, Lang T, Reiberger T, Haltmayer H, Gschwantler M. Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria. PLoS One 2020;15:e0229239. [PMID: 32155165 DOI: 10.1371/journal.pone.0229239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
31 Binka M, Janjua NZ, Grebely J, Estes C, Schanzer D, Kwon JA, Shoukry NH, Kwong JC, Razavi H, Feld JJ, Krajden M. Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model. JAMA Netw Open 2020;3:e204192. [PMID: 32374397 DOI: 10.1001/jamanetworkopen.2020.4192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
32 Grau-López L, Marcos-Fosch C, Daigre C, Palma-Alvarez RF, Rando-Segura A, Llaneras J, Perea-Ortueta M, Rodriguez-Frias F, Martínez-Luna N, Riveiro-Barciela M, Ramos-Quiroga JA, Colom J, Esteban R, Buti M. Barriers to linkage to care in hepatitis C patients with substance use disorders and dual diagnoses, despite centralized management. Therap Adv Gastroenterol 2021;14:17562848211016563. [PMID: 34471422 DOI: 10.1177/17562848211016563] [Reference Citation Analysis]
33 Kileng H, Gutteberg T, Goll R, Paulssen EJ. Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study. BMC Infect Dis 2019;19:189. [PMID: 30808290 DOI: 10.1186/s12879-019-3832-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Llibre A, Shimakawa Y, Mottez E, Ainsworth S, Buivan TP, Firth R, Harrison E, Rosenberg AR, Meritet JF, Fontanet A, Castan P, Madejón A, Laverick M, Glass A, Viana R, Pol S, McClure CP, Irving WL, Miele G, Albert ML, Duffy D. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut 2018;67:2017-24. [PMID: 29615488 DOI: 10.1136/gutjnl-2017-315783] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
35 Tavoschi L, Vroling H, Madeddu G, Babudieri S, Monarca R, Vonk Noordegraaf-Schouten M, Beer N, Gomes Dias J, O'Moore É, Hedrich D, Oordt-Speets A. Active Case Finding for Communicable Diseases in Prison Settings: Increasing Testing Coverage and Uptake Among the Prison Population in the European Union/European Economic Area. Epidemiol Rev 2018;40:105-20. [PMID: 29648594 DOI: 10.1093/epirev/mxy001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
36 Koopsen J, van Steenbergen JE, Richardus JH, Prins M, Op de Coul ELM, Croes EA, Heil J, Zuure FR, Veldhuijzen IK. Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population. Epidemiol Infect 2019;147:e147. [PMID: 30869044 DOI: 10.1017/S0950268819000359] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
37 van Dijk M, Brakenhoff SM, Isfordink CJ, Cheng WH, Blokzijl H, Boland G, Dofferhoff ASM, van Hoek B, van Nieuwkoop C, Sonneveld MJ, van der Valk M, Drenth JPH, de Knegt RJ. The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030. J Clin Med 2021;10:4562. [PMID: 34640576 DOI: 10.3390/jcm10194562] [Reference Citation Analysis]
38 Shahid I, Alzahrani AR, Al-Ghamdi SS, Alanazi IM, Rehman S, Hassan S. Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises. Diagnostics (Basel) 2021;11:1253. [PMID: 34359335 DOI: 10.3390/diagnostics11071253] [Reference Citation Analysis]
39 Silva JM, Silva MJ, Calinas F, Nogueira PJ. Burden of Liver Cirrhosis in Portugal between 2010 and 2017. GE Port J Gastroenterol 2021;28:153-61. [PMID: 34056037 DOI: 10.1159/000510729] [Reference Citation Analysis]
40 Velosa J, Macedo G. Elimination of Hepatitis C in Portugal: An Urban Legend? GE Port J Gastroenterol 2020;27:166-71. [PMID: 32509922 DOI: 10.1159/000505582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
41 Rossi C, Young J, Martel-Laferrière V, Walmsley S, Cooper C, Wong A, Gill MJ, Klein MB; Canadian Co-Infection Cohort Investigators . Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV-Coinfected Patients in Clinical Care. Open Forum Infect Dis 2019;6:ofz055. [PMID: 30882016 DOI: 10.1093/ofid/ofz055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
42 Nielsen S, Hansen JF, Hay G, Cowan S, Jepsen P, Omland LH, Krarup HB, Søholm J, Lazarus JV, Weis N, Øvrehus A, Christensen PB. Hepatitis C prevalence in Denmark in 2016-An updated estimate using multiple national registers. PLoS One 2020;15:e0238203. [PMID: 32881877 DOI: 10.1371/journal.pone.0238203] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
43 Litzroth A, Suin V, Wyndham-Thomas C, Quoilin S, Muyldermans G, Vanwolleghem T, Kabamba-Mukadi B, Verburgh V, Jacques M, Van Gucht S, Hutse V. Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up. BMC Public Health 2019;19:39. [PMID: 30621662 DOI: 10.1186/s12889-018-6347-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
44 Huang Y, Pan H, Gao Q, Lv P, Xu X, Zhao Z. The role of a two-assay serological testing strategy for anti-HCV screening in low-prevalence populations. Sci Rep 2021;11:8689. [PMID: 33888806 DOI: 10.1038/s41598-021-88138-2] [Reference Citation Analysis]
45 Schmidbauer C, Chromy D, Schmidbauer V, Bauer D, Apata M, Nguyen D, Mandorfer M, Simbrunner B, Rieger A, Mayer F, Schmidt R, Holzmann H, Trauner M, Gschwantler M, Reiberger T. Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. Liver Int 2020;40:787-96. [PMID: 32017359 DOI: 10.1111/liv.14399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
46 Pitcher AB, Borquez A, Skaathun B, Martin NK. Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies. J Theor Biol 2019;481:194-201. [PMID: 30452959 DOI: 10.1016/j.jtbi.2018.11.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
47 Bobardt M, Ramirez CM, Baum MM, Ure D, Foster R, Gallay PA. The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance. PLoS One 2021;16:e0251934. [PMID: 34014993 DOI: 10.1371/journal.pone.0251934] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Flisiak R, Zarębska-Michaluk D, Janczewska E, Łapiński T, Rogalska M, Karpińska E, Mikuła T, Bolewska B, Białkowska J, Flejscher-Stępniewska K, Tomasiewicz K, Karwowska K, Pazgan-Simon M, Piekarska A, Berak H, Tronina O, Garlicki A, Jaroszewicz J. Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy. Cancers (Basel) 2021;13:3694. [PMID: 34359594 DOI: 10.3390/cancers13153694] [Reference Citation Analysis]
49 Pradat P, Virlogeux V, Trépo E. Epidemiology and Elimination of HCV-Related Liver Disease. Viruses 2018;10:E545. [PMID: 30301201 DOI: 10.3390/v10100545] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
50 Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol 2021; 27(26): 4004-4017 [PMID: 34326610 DOI: 10.3748/wjg.v27.i26.4004] [Reference Citation Analysis]
51 Papic N, Radmanic L, Dusek D, Kurelac I, Zidovec Lepej S, Vince A. Trends of Late Presentation to Care in Patients with Chronic Hepatitis C during a 10-Year Period in Croatia. Infect Dis Rep 2020;12:74-81. [PMID: 33187150 DOI: 10.3390/idr12030016] [Reference Citation Analysis]
52 Falla AM, Ahmad AA, Duffell E, Noori T, Veldhuijzen IK. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries. BMC Infect Dis 2018;18:42. [PMID: 29338702 DOI: 10.1186/s12879-017-2908-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
53 Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393:1319-1329. [PMID: 30704789 DOI: 10.1016/s0140-6736(18)32277-3] [Cited by in Crossref: 116] [Cited by in F6Publishing: 52] [Article Influence: 38.7] [Reference Citation Analysis]
54 Kracht PAM, Arends JE, van Erpecum KJ, Urbanus A, Willemse JA, Hoepelman AIM, Croes EA. Strategies for achieving viral hepatitis C micro-elimination in the Netherlands. Hepatol Med Policy. 2018;3:12. [PMID: 30288334 DOI: 10.1186/s41124-018-0040-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
55 Martin NK, Boerekamps A, Hill AM, Rijnders BJA. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it? J Int AIDS Soc 2018;21 Suppl 2:e25062. [PMID: 29633560 DOI: 10.1002/jia2.25062] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
56 Schaefer B, Viveiros A, Al-Zoairy R, Blach S, Brandon S, Razavi H, Dorn L, Finkenstedt A, Effenberger M, Graziadei I, Sarcletti M, Tilg H, Zoller H. Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030. PLoS One 2018;13:e0200750. [PMID: 30001427 DOI: 10.1371/journal.pone.0200750] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Castro R, Perazzo H, de Araujo LAMM, Gutierres IG, Grinsztejn B, Veloso VG. Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis. PLoS One 2020;15:e0229143. [PMID: 32084187 DOI: 10.1371/journal.pone.0229143] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
58 Dar GA, Yattoo GN, Gulzar GM, Sodhi JS, Gorka S, Laway MA. Treatment of Chronic Hepatitis C Genotype 3 With Ledipasvir and Sofosbuvir: An Observational Study. J Clin Exp Hepatol 2021;11:227-31. [PMID: 33746448 DOI: 10.1016/j.jceh.2020.06.011] [Reference Citation Analysis]
59 Brouard C, Pillonel J, Boussac M, de Lédinghen V, Rachas A, Silvain C, Lydié N, Chevaliez S, Pioche C, Durand J, Lot F, Delarocque-Astagneau E. French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long. BMC Infect Dis 2020;20:759. [PMID: 33059617 DOI: 10.1186/s12879-020-05478-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
60 Buti M, Domínguez-Hernández R, Casado MÁ, Sabater E, Esteban R. Healthcare value of implementing hepatitis C screening in the adult general population in Spain. PLoS One 2018;13:e0208036. [PMID: 30485377 DOI: 10.1371/journal.pone.0208036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
61 Cipriano LE, Goldhaber-Fiebert JD. Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy Pract 2018;3:2381468318776634. [PMID: 30288448 DOI: 10.1177/2381468318776634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
62 Yao BB, Fredrick LM, Schnell G, Kowdley KV, Kwo PY, Poordad F, Nguyen K, Lee SS, George C, Wong F, Gane E, Abergel A, Spearman CW, Nguyen T, Hung Le M, Pham TT, Mensa F, Asselah T. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. Liver Int 2020;40:2385-93. [PMID: 32445613 DOI: 10.1111/liv.14535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Mei YY, Chen YM, Wu YK, Zhang XH, Xu WX. Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection. Can J Gastroenterol Hepatol 2020;2020:8872120. [PMID: 33194875 DOI: 10.1155/2020/8872120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Nakitanda AO, Duffell E. Hospital discharges of hepatocellular carcinoma and non-alcohol related cirrhosis in the EU/EEA and United Kingdom: a descriptive analysis of 2004-2015 data. Infect Dis (Lond) 2020;52:816-27. [PMID: 32838640 DOI: 10.1080/23744235.2020.1799068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Danesh G, Virlogeux V, Ramière C, Charre C, Cotte L, Alizon S. Quantifying transmission dynamics of acute hepatitis C virus infections in a heterogeneous population using sequence data. PLoS Pathog 2021;17:e1009916. [PMID: 34520487 DOI: 10.1371/journal.ppat.1009916] [Reference Citation Analysis]
66 Brouard C, Saboni L, Gautier A, Chevaliez S, Rahib D, Richard JB, Barin F, Larsen C, Sommen C, Pillonel J, Delarocque-Astagneau E, Lydié N, Lot F; 2016 Health Barometer Group. HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy. BMC Infect Dis 2019;19:896. [PMID: 31660879 DOI: 10.1186/s12879-019-4493-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
67 Gaspar R, Liberal R, Tavares J, Morgado R, Macedo G. HIPPOCRATES® project: A proof of concept of a collaborative program for hepatitis C virus micro-elimination in a prison setting. World J Hepatol 2020; 12(12): 1314-1325 [PMID: 33442457 DOI: 10.4254/wjh.v12.i12.1314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Green V, Roytman M, Komatsu H. Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review. Case Reports in Hepatology 2022;2022:1-5. [DOI: 10.1155/2022/3556780] [Reference Citation Analysis]
69 Canivet CM, Smati S, Lannes A, Brisseau J, Judon L, Roch ML, Cariou B, Bellanger W, Guerci B, Boursier J. Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners. Clin Res Hepatol Gastroenterol 2021;:101848. [PMID: 34922062 DOI: 10.1016/j.clinre.2021.101848] [Reference Citation Analysis]